<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39206253</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2590-1567</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><PubDate><Year>2024</Year><Month>Dec</Month></PubDate></JournalIssue><Title>International journal of pharmaceutics: X</Title><ISOAbbreviation>Int J Pharm X</ISOAbbreviation></Journal><ArticleTitle>An examination of process models and model risk frameworks for pharmaceutical manufacturing.</ArticleTitle><Pagination><StartPage>100274</StartPage><MedlinePgn>100274</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100274</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijpx.2024.100274</ELocationID><Abstract><AbstractText>Process models are a growing tool for pharmaceutical manufacturing process design and control. The Industry 4.0 paradigm promises to increase the amount of data available to understand manufacturing processes. Tools such as Artificial Intelligence (AI) might accelerate process development and allow better predictions of process trajectories. Several examples of process improvements realized through the application of process models have been shown in lyophilization, chromatography, fluid bed drying, bioreactor control, continuous direct compression, and wet granulation. An important consideration of implementing a process model is determining the impact of the model on the quality of the product and the risks associated with model maintenance over the product lifecycle. Several regulatory documents address risk-based considerations for process models. This work discusses existing risk-based frameworks for model validation and lifecycle maintenance that could aid the adoption of process models in pharmaceutical manufacturing. Hypothetical case studies illustrate the implications of applying a model risk framework to facilitate model validation and lifecycle maintenance in the manufacture of pharmaceuticals and biological products.</AbstractText><CopyrightInformation>Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>O'Connor</LastName><ForeName>Thomas F</ForeName><Initials>TF</Initials><AffiliationInfo><Affiliation>Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, MD 20993, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chatterjee</LastName><ForeName>Sharmista</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, MD 20993, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>Johnny</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD 20993, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hernán Pérez de la Ossa</LastName><ForeName>Dolores</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>European Medicines Agency, Human Division, Domenico Scarlattilaan 6, 1083 HS, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez-Peyrat</LastName><ForeName>Leticia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>French National Agency for Medicines and Health Products Safety, F-93285, Saint-Denis, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Quality Innovation Group (QIG), European Medicines Agency (EMA), Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoefnagel</LastName><ForeName>Marcel H N</ForeName><Initials>MHN</Initials><AffiliationInfo><Affiliation>Quality Innovation Group (QIG), European Medicines Agency (EMA), Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CBG-MEB (Medicines Evaluation Board), Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fisher</LastName><ForeName>Adam C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, MD 20993, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int J Pharm X</MedlineTA><NlmUniqueID>101753452</NlmUniqueID><ISSNLinking>2590-1567</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Model lifecycle maintenance</Keyword><Keyword MajorTopicYN="N">Model risk assessment</Keyword><Keyword MajorTopicYN="N">Model validation</Keyword><Keyword MajorTopicYN="N">Pharmaceuticals</Keyword><Keyword MajorTopicYN="N">Process models</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>29</Day><Hour>4</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39206253</ArticleId><ArticleId IdType="pmc">PMC11350267</ArticleId><ArticleId IdType="doi">10.1016/j.ijpx.2024.100274</ArticleId><ArticleId IdType="pii">S2590-1567(24)00046-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arden N.S., Fisher A.C., Tyner K., Yu L.X., Lee S.L., Kopcha M. Industry 4.0 for pharmaceutical manufacturing:
Preparing for the Smart Factories of the Future. Int. J. Pharm. 2021;602:120554. https://www.sciencedirect.com/science/article/pii/S0378517321003598 March 29.</Citation><ArticleIdList><ArticleId IdType="pubmed">33794326</ArticleId></ArticleIdList></Reference><Reference><Citation>Assessing the Credibility of Computational Modeling
and Simulation in Medical Device Submissions: Guidance for
Industry and Food and Drug Administration Staff U.S. Department of Health and Human Services - Food
and Drug Administration - Center for Devices and Radiological
Health. 2023. https://www.fda.gov/media/154985/download</Citation></Reference><Reference><Citation>Assessing the credibility of computational modeling
through verification and validation: Application to medical
devices V&amp;V 40 American Society of Mechanical
Engineers. 2018. https://www.asme.org/codes-standards/find-codes-standards/v-v-40-assessing-credibility-computational-modeling-verification-validation-application-medical-devices</Citation></Reference><Reference><Citation>Assessing the credibility of computational modeling
through verification and validation: Application to medical
devices V&amp;V 40 American Society of Mechanical
Engineers. 2018. https://www.asme.org/codes-standards/find-codes-standards/v-v-40-assessing-credibility-computational-modeling-verification-validation-application-medical-devices</Citation></Reference><Reference><Citation>Assessing the credibility of computational modeling
through verification and validation: Application to medical
devices V&amp;V 40 American Society of Mechanical
Engineers. 2018. https://www.asme.org/codes-standards/find-codes-standards/v-v-40-assessing-credibility-computational-modeling-verification-validation-application-medical-devices</Citation></Reference><Reference><Citation>Bayrak E.S., Wang T., Tulsyan A., Coufal M., Undey C.  IFAC-PapersOnLine; 2018. Product Attribute Forecast:
Adaptive Model Selection Using Real-Time Machine
Learning.https://www.sciencedirect.com/science/article/pii/S240589631831963 October 8.</Citation></Reference><Reference><Citation>Bideault G., Scaccia A., Zahel T., Landeringer R.W., Daluwatte C. Verification and validation of computational models
used in biopharmaceutical manufacturing: potential Application
of the ASME verification and validation 40 standard and FDA
proposed AI/ML Model Life Cycle Management
Framework. J. Pharm. Sci. 2021;110:1540. https://www.sciencedirect.com/science/article/abs/pii/S0022354921000319 January 23.</Citation><ArticleIdList><ArticleId IdType="pubmed">33493480</ArticleId></ArticleIdList></Reference><Reference><Citation>BioPhorum . 2021. Industry Proposal: Regulatory Submission and Lifecycle Management Strategy of Models used in the Manufacture of Pharmaceutical and Biological Products. January.</Citation><ArticleIdList><ArticleId IdType="doi">10.46220/2020REG002</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee S., Moore C.M.V., Nasr M.M.  DigitalCommons@University of Nebraska -
Lincoln; 2017. An Overview of the Role of Mathematical Models in
Implementation of Quality by Design Paradigm for Drug
Development and Manufacture.https://digitalcommons.unl.edu/usfda/23/</Citation></Reference><Reference><Citation>Cogoni G., Liu Y.A., Husain A., Alam M.A., Kamyar R. A hybrid NIR-Soft Sensor Method for real time in-process control during continuous direct compression manufacturing operations. Int. J. Pharm. 2021;602 doi: 10.1016/j.ijpharm.2021.120620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2021.120620</ArticleId><ArticleId IdType="pubmed">33892059</ArticleId></ArticleIdList></Reference><Reference><Citation>Cogoni G., Liu Y.A., Husain A., Alam M.A., Kamyar R. A hybrid NIR-Soft Sensor Method for real time in-process control during continuous direct compression manufacturing operations. Int. J. Pharm. 2021;602 doi: 10.1016/j.ijpharm.2021.120620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2021.120620</ArticleId><ArticleId IdType="pubmed">33892059</ArticleId></ArticleIdList></Reference><Reference><Citation>Cogoni G., Liu Y.A., Husain A., Alam M.A., Kamyar R. A hybrid NIR-Soft Sensor Method for real time in-process control during continuous direct compression manufacturing operations. Int. J. Pharm. 2021;602 doi: 10.1016/j.ijpharm.2021.120620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2021.120620</ArticleId><ArticleId IdType="pubmed">33892059</ArticleId></ArticleIdList></Reference><Reference><Citation>Craven S., Whelan J., Glennon B. Glucose concentration control of a fed-batch mammalian
cell bioprocess using a nonlinear model Predictive
Controller. J. Process Control. 2014;24:344. https://www.sciencedirect.com/science/article/abs/pii/S0959152414000584 March 21.</Citation></Reference><Reference><Citation>Ding C., Gerberich C., Ierapetritou M. Hybrid model development for parameter estimation and process optimization of hydrophobic interaction chromatography. J. Chromatogr. A. 2023;1703 doi: 10.1016/j.chroma.2023.464113. ISSN 0021-9673.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chroma.2023.464113</ArticleId><ArticleId IdType="pubmed">37267655</ArticleId></ArticleIdList></Reference><Reference><Citation>Doron G., Klontzas M.E., Mantalaris A., Guldberg R.E., Temenoff J.S. Multiomics characterization of mesenchymal stromal cells cultured in monolayer and as aggregates. Biotechnol. Bioeng. 2020;117(6):1761–1778. Jun.</Citation><ArticleIdList><ArticleId IdType="pubmed">32100872</ArticleId></ArticleIdList></Reference><Reference><Citation>EMA CHMP guideline on the use of near infrared spectroscopy by
the pharmaceutical industry and the data requirements for new
submissions and variations (EMEA/CHMP/CVMP/QWP/17760/2009
Rev2) 2014. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-use-near-infrared-spectroscopy-pharmaceutical-industry-and-data-requirements-new-submissions-and-variations_en.pdf June.</Citation></Reference><Reference><Citation>EMA CHMP guideline on the use of near infrared spectroscopy by
the pharmaceutical industry and the data requirements for new
submissions and variations (EMEA/CHMP/CVMP/QWP/17760/2009
Rev2) 2014. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-use-near-infrared-spectroscopy-pharmaceutical-industry-and-data-requirements-new-submissions-and-variations_en.pdf June.</Citation></Reference><Reference><Citation>EMA Preliminary QIG Considerations regarding Pharmaceutical 5 Process Models . 2024. Quality Innovation Group | European Medicines Agency (europa.eu) February.</Citation></Reference><Reference><Citation>Erdemir A., Mulugeta L., Ku J.P., et al. Credible practice of modeling and simulation in healthcare: ten rules from a multidisciplinary perspective. J. Transl. Med. 2020;18:369. doi: 10.1186/s12967-020-02540-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-020-02540-4</ArticleId><ArticleId IdType="pmc">PMC7526418</ArticleId><ArticleId IdType="pubmed">32993675</ArticleId></ArticleIdList></Reference><Reference><Citation>EU CHMP . 2015. guideline on manufacture of the finished dosage form (EMA/CHMP/QWP/245074/2015)</Citation></Reference><Reference><Citation>Executive Order 14110 of October 30 Safe, Secure, and Trustworthy Development and Use of
Artificial Intelligence. 2023. https://www.federalregister.gov/d/2023-24283</Citation></Reference><Reference><Citation>Garcia-Munoz S., Butterbaugh A., Leavesley I., Manley L.F., Slade D., Bermingham S. AIChE Online Library; 2017. A Flowsheet Model for the Development of a Continuous Process for Pharmaceutical Tablets: An Industrial Perspective.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/aic.15967</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbons L., Maslanka F., Le N., Magill A., Singh P., Mclaughlin J., Madden F., Hayes R., McCarthy B., Rode C., O’Mahony J., Rea R., O’Mahony-Hartnett C. An assessment of the impact of Raman based glucose feedback control on CHO cell bioreactor process development. Biotechnol. Prog. 2023 doi: 10.1002/btpr.3371. June 27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/btpr.3371</ArticleId><ArticleId IdType="pubmed">37365962</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J., O’Connor T., Ahmed K., Chatterjee S., Garvin C., Ghosh K., Ierapetritou M., Jeffers M., Pla D.L., Lee S.L., Lovett D., Lynberg O., Mack J., McManus E., Romero-Torres S., Undey C., Venkatasubramanian V., Warman M. AIChE Online Library; 2020, November 3. AiChe PD2M Advanced Process Control (APC) Workshop-Moving APC Forward in the Pharmaceutical Industry.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/amp2.10071</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J., O’Connor T., Ahmed K., Chatterjee S., Garvin C., Ghosh K., Ierapetritou M., Jeffers M., Pla D.L., Lee S.L., Lovett D., Lynberg O., Mack J., McManus E., Romero-Torres S., Undey C., Venkatasubramanian V., Warman M. AIChE Online Library; 2020, November 3. AiChe PD2M Advanced Process Control (APC) Workshop-Moving APC Forward in the Pharmaceutical Industry.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/amp2.10071</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurley S., Tantuccio A., Escotet-Espinoza M.S., Flamm M., Metzger M. Development and use of a residence time distribution (RTD) model control strategy for a continuous manufacturing drug product pharmaceutical process. Pharmaceutics. 2022;14(2):355. doi: 10.3390/pharmaceutics14020355.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics14020355</ArticleId><ArticleId IdType="pmc">PMC8874656</ArticleId><ArticleId IdType="pubmed">35214087</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurley S., Tantuccio A., Escotet-Espinoza M.S., Flamm M., Metzger M. Development and use of a residence time distribution (RTD) model control strategy for a continuous manufacturing drug product pharmaceutical process. Pharmaceutics. 2022;14(2):355. doi: 10.3390/pharmaceutics14020355.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics14020355</ArticleId><ArticleId IdType="pmc">PMC8874656</ArticleId><ArticleId IdType="pubmed">35214087</ArticleId></ArticleIdList></Reference><Reference><Citation>ICH . 2023. guideline on Q13 on continuous manufacturing of drug substances and drug products. October 7.</Citation></Reference><Reference><Citation>ICH Quality Implementation Working
Group, editor. ICH quality implementation working group - points
to consider (R2) - ICH-endorsed guide for ICH Q8/Q9/Q10
implementation. Points to consider (R2) - ICH-Endorsed Guide for ICH
Q8/Q9/Q10 Implementation - ECA Academy; 2011. https://www.gmp-compliance.org/guidelines/gmp-guideline/ich-quality-implementation-working-group-points-to-consider-r2-ich-endorsed-guide-for-ich-q8-q9-q10-implementation December 6.</Citation></Reference><Reference><Citation>ICH Quality Implementation Working
Group, editor. ICH quality implementation working group - points
to consider (R2) - ICH-endorsed guide for ICH Q8/Q9/Q10
implementation. Points to consider (R2) - ICH-Endorsed Guide for ICH
Q8/Q9/Q10 Implementation - ECA Academy; 2011. https://www.gmp-compliance.org/guidelines/gmp-guideline/ich-quality-implementation-working-group-points-to-consider-r2-ich-endorsed-guide-for-ich-q8-q9-q10-implementation December 6.</Citation></Reference><Reference><Citation>Kamyar R., Lauri Pla D., Husain A., Cogoni G., Wang Z. Soft sensor for real-time estimation of tablet potency in continuous direct compression manufacturing operation. Int. J. Pharm. 2021;602 doi: 10.1016/j.ijpharm.2021.120624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2021.120624</ArticleId><ArticleId IdType="pubmed">33892055</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamyar R., Lauri Pla D., Husain A., Cogoni G., Wang Z. Soft sensor for real-time estimation of tablet potency in continuous direct compression manufacturing operation. Int. J. Pharm. 2021;602 doi: 10.1016/j.ijpharm.2021.120624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2021.120624</ArticleId><ArticleId IdType="pubmed">33892055</ArticleId></ArticleIdList></Reference><Reference><Citation>Kourti T., Lepore J., Liesum L., Nasr M., Chatterjee S., Moore C.M.V., Korakianiti E. Scientific and Regulatory Considerations for
Implementing Mathematical Models in the Quality by Design (QbD)
Framework. Pharm. Eng. 2014;34(6) https://ispe.org/sites/default/files/pe/online-exclusives/14ND-online_Kourti.pdf</Citation></Reference><Reference><Citation>Kuemmel C., Yang Y., Zhang X., Florian J., Zhu H., Tegenge M., Huang S.-M., Wang Y., Morrison T., Zineh I. Consideration of a credibility assessment framework in
model-informed drug development: potential application to
physiologically-based pharmacokinetic modeling and
simulation. CPT Pharmacometrics Syst.
Pharmacol. 2019, November 10;9(1):21–28. https://pubmed.ncbi.nlm.nih.gov/31652029/</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6966181</ArticleId><ArticleId IdType="pubmed">31652029</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuemmel C., Yang Y., Zhang X., Florian J., Zhu H., Tegenge M., Huang S.-M., Wang Y., Morrison T., Zineh I. Consideration of a credibility assessment framework in
model-informed drug development: potential application to
physiologically-based pharmacokinetic modeling and
simulation. CPT Pharmacometrics Syst.
Pharmacol. 2019, November 10;9(1):21–28. https://pubmed.ncbi.nlm.nih.gov/31652029/</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6966181</ArticleId><ArticleId IdType="pubmed">31652029</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar V., Leweke S., Heymann W., von Lieres E., Schlegel F., Westerberg K., Lenhoff A.M. Robust mechanistic modeling of protein ion-exchange chromatography. J. Chromatogr. A. 2021;1660 doi: 10.1016/j.chroma.2021.462669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chroma.2021.462669</ArticleId><ArticleId IdType="pubmed">34800897</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauri Pla D., Kamyar R., Hashemian N., Mehdizadeh H., Moshgbar M. Moisture soft sensor for batch fluid bed dryers: A practical approach. Powder Technol. 2018;326:69–77. doi: 10.1016/j.powtec.2017.11.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.powtec.2017.11.056</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauri Pla D., Kamyar R., Hashemian N., Mehdizadeh H., Moshgbar M. Moisture soft sensor for batch fluid bed dryers: A practical approach. Powder Technol. 2018;326:69–77. doi: 10.1016/j.powtec.2017.11.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.powtec.2017.11.056</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy O., Kuai R., Siren E.M., Bhere D., Milton Y., Nissar N., De Biasio M., Heinelt M., Reeve B., Abdi R., Alturki M. Shattering barriers toward clinically meaningful MSC therapies. Sci. Adv. 2020;6(30) eaba6884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7439491</ArticleId><ArticleId IdType="pubmed">32832666</ArticleId></ArticleIdList></Reference><Reference><Citation>Galbraith S.C., Cha B., Huang Z., Park S., Liu H., Meyer R.F., Flamm M.H., Hurley S., Zhang-Plasket F., Yoon S. Integrated modeling of a continuous direct compression
tablet manufacturing process: A production scale case
study. Powder Technol. 2019;354:199. https://www.sciencedirect.com/science/article/abs/pii/S0032591019304255 June 5.</Citation></Reference><Reference><Citation>Lipsitz Y., Timmins N., Zandstra P. Quality cell therapy manufacturing by
design. Nat. Biotechnol. 2016;34:393–400. https://www.nature.com/articles/nbt.3525 April 7.</Citation><ArticleIdList><ArticleId IdType="pubmed">27054995</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L. Antibody glycosylation and its impact on the
pharmacokinetics and pharmacodynamics of monoclonal antibodies
and FC-fusion proteins. J. Pharm. Sci. 2015;104(6):1866–1884. https://pubmed.ncbi.nlm.nih.gov/25872915/ April 15.</Citation><ArticleIdList><ArticleId IdType="pubmed">25872915</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y.C., Acevedo D., Yang X., Naimi S., Wu W.-L., Pavurala N., Nagy Z.K., O’Connor T.F. ACS Publications; 2020. Population Balance Model Development Verification and Validation of Cooling Crystallization of Carbamazepine. June 20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.cgd.0c00434</ArticleId></ArticleIdList></Reference><Reference><Citation>Mautner K., Gottschalk M., Boden S.D., Akard A., Bae W.C., Black L., Boggess B., Chatterjee P., Chung C.B., Easley K.A., Gibson G. Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nat. Med. 2023;29(12):3120–3126. Dec.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10719084</ArticleId><ArticleId IdType="pubmed">37919438</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Benito M., Lee K.T., Kaydanov D., Verrier H.M., Blackwood D.O., Doshi P. Digital twin of a continuous direct compression line for drug product and process design using a hybrid flowsheet modelling approach. Int. J. Pharm. 2022;628 doi: 10.1016/j.ijpharm.2022.122336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2022.122336</ArticleId><ArticleId IdType="pubmed">36309292</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Benito M., Lee K.T., Kaydanov D., Verrier H.M., Blackwood D.O., Doshi P. Digital twin of a continuous direct compression line for drug product and process design using a hybrid flowsheet modelling approach. Int. J. Pharm. 2022;628 doi: 10.1016/j.ijpharm.2022.122336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2022.122336</ArticleId><ArticleId IdType="pubmed">36309292</ArticleId></ArticleIdList></Reference><Reference><Citation>Q12 Technical and Regulatory Considerations for
Pharmaceutical Product Lifecycle Management Guidance for
Industry U.S. Department of Health and Human Services - Food
and Drug Administration - Center for Drug Evaluation and
Research (CDER) - Center for Biologics Evaluation and Research
(CBER) 2021. https://www.fda.gov/media/148476/download May.</Citation></Reference><Reference><Citation>Rashedi M., Khodabandehlou H., Demers M., Wang T., Garvin C.  IFAC-PapersOnLine; 2022. Model Predictive Controller Design for bioprocesses
based on machine learning algorithms.https://www.sciencedirect.com/science/article/pii/S2405896322008217 August 5.</Citation><ArticleIdList><ArticleId IdType="pubmed">37395526</ArticleId></ArticleIdList></Reference><Reference><Citation>Rashedi M., Khodabandehlou H., Demers M., Wang T., Garvin C.  IFAC-PapersOnLine; 2022. Model Predictive Controller Design for bioprocesses
based on machine learning algorithms.https://www.sciencedirect.com/science/article/pii/S2405896322008217 August 5.</Citation><ArticleIdList><ArticleId IdType="pubmed">37395526</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy J.V., Raudenbush K., Papoutsakis E.T., Ierapetritou M. Cell-culture process optimization via model-based predictions of metabolism and protein glycosylation. Biotechnol. Adv. 2023;67</Citation><ArticleIdList><ArticleId IdType="pubmed">37257729</ArticleId></ArticleIdList></Reference><Reference><Citation>Rischawy F., Saleh D., Hahn T., Oelmeier S., Spitz J., Kluters S. Good modeling practice for industrial chromatography: Mechanistic modeling of ion exchange chromatography of a bispecific antibody. Comput. Chem. Eng. 2019;130 doi: 10.1016/j.compchemeng.2019.106532.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.compchemeng.2019.106532</ArticleId></ArticleIdList></Reference><Reference><Citation>Rischawy F., Saleh D., Hahn T., Oelmeier S., Spitz J., Kluters S. Good modeling practice for industrial chromatography: Mechanistic modeling of ion exchange chromatography of a bispecific antibody. Comput. Chem. Eng. 2019;130 doi: 10.1016/j.compchemeng.2019.106532.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.compchemeng.2019.106532</ArticleId></ArticleIdList></Reference><Reference><Citation>Rischawy F., Saleh D., Hahn T., Oelmeier S., Spitz J., Kluters S. Good modeling practice for industrial chromatography: Mechanistic modeling of ion exchange chromatography of a bispecific antibody. Comput. Chem. Eng. 2019;130 doi: 10.1016/j.compchemeng.2019.106532.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.compchemeng.2019.106532</ArticleId></ArticleIdList></Reference><Reference><Citation>Rischawy F., Saleh D., Hahn T., Oelmeier S., Spitz J., Kluters S. Good modeling practice for industrial chromatography: Mechanistic modeling of ion exchange chromatography of a bispecific antibody. Comput. Chem. Eng. 2019;130 doi: 10.1016/j.compchemeng.2019.106532.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.compchemeng.2019.106532</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers A.J., Inamdar C., Ierapetritou M.G.  The State University of New Jersey; Rutgers: 2014. An Integrated Approach to Simulation of Pharmaceutical
Processes for Solid Drug Manufacture.https://www.researchwithrutgers.com/en/publications/an-integrated-approach-to-simulation-of-pharmaceutical-processes April 2.</Citation></Reference><Reference><Citation>Roy K., Wang B., Chen R.Q., Li J. Interfacing data science with cell therapy manufacturing: where we are and where we need to be. Cytotherapy S1465-3249(24)00099-9Apr. 2024;4</Citation><ArticleIdList><ArticleId IdType="pubmed">38842968</ArticleId></ArticleIdList></Reference><Reference><Citation>Saleh D., Wang G., Müller B., Rischawy F., Kluters S., Studts J., Hubbuch J. Straightforward method for calibration of mechanistic cation exchange chromatography models for industrial applications. Biotechnol. Prog. 2020;36(4) doi: 10.1002/btpr.2984.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/btpr.2984</ArticleId><ArticleId IdType="pubmed">32087049</ArticleId></ArticleIdList></Reference><Reference><Citation>Saleh D., Wang G., Mueller B., Rischawy F., Kluters S., Studts J., Hubbuch J. Cross-scale quality assessment of a mechanistic cation exchange chromatography model. Biotechnol. Prog. 2020;37(1) doi: 10.1002/btpr.3081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/btpr.3081</ArticleId><ArticleId IdType="pubmed">32926575</ArticleId></ArticleIdList></Reference><Reference><Citation>Saleh D., Wang G., Mueller B., Rischawy F., Kluters S., Studts J., Hubbuch J. Cross-scale quality assessment of a mechanistic cation exchange chromatography model. Biotechnol. Prog. 2020;37(1) doi: 10.1002/btpr.3081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/btpr.3081</ArticleId><ArticleId IdType="pubmed">32926575</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepard T., Scott G., Cole S., Nordmark A., Bouzom F. Physiologically based models in regulatory submissions: output from the ABPI/MHRA forum on physiologically based modeling and simulation. CPT Pharmacometrics Syst. Pharmacol. 2015;4(4):221–225. doi: 10.1002/psp4.30. Epub 2015 Apr 2. PMID: 26225245; PMCID: PMC4429575.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/psp4.30</ArticleId><ArticleId IdType="pmc">PMC4429575</ArticleId><ArticleId IdType="pubmed">26225245</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasan A., Sathiyanathan P., Yin L., Liu T.M., Lam A., Ravikumar M., Smith R.A., Loh H.P., Zhang Y., Ling L., Ng S.K. Strategies to enhance immunomodulatory properties and reduce heterogeneity in mesenchymal stromal cells during ex vivo expansion. Cytotherapy. 2022;24(5):456–472. May 1.</Citation><ArticleIdList><ArticleId IdType="pubmed">35227601</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasan A., Sathiyanathan P., Yin L., Liu T.M., Lam A., Ravikumar M., Smith R.A., Loh H.P., Zhang Y., Ling L., Ng S.K. Strategies to enhance immunomodulatory properties and reduce heterogeneity in mesenchymal stromal cells during ex vivo expansion. Cytotherapy. 2022;24(5):456–472. May 1.</Citation><ArticleIdList><ArticleId IdType="pubmed">35227601</ArticleId></ArticleIdList></Reference><Reference><Citation>Tchessalov S., Latshaw D., Nulu S., Bentley M., Tharp T., Ewan S., Chen X. Application of first principles primary drying model to lyophilization process design and transfer: Case studies from the industry. J. Pharm. Sci. 2021;110(2021):968–981. doi: 10.1016/j.xphs.2020.11.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xphs.2020.11.013</ArticleId><ArticleId IdType="pubmed">33248058</ArticleId></ArticleIdList></Reference><Reference><Citation>Tchessalov S., Latshaw D., Nulu S., Bentley M., Tharp T., Ewan S., Chen X. Application of first principles primary drying model to lyophilization process design and transfer: Case studies from the industry. J. Pharm. Sci. 2021;110(2021):968–981. doi: 10.1016/j.xphs.2020.11.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xphs.2020.11.013</ArticleId><ArticleId IdType="pubmed">33248058</ArticleId></ArticleIdList></Reference><Reference><Citation>Tchessalov S., Latshaw D., Nulu S., Bentley M., Tharp T., Ewan S., Chen X. Application of first principles primary drying model to lyophilization process design and transfer: Case studies from the industry. J. Pharm. Sci. 2021;110(2021):968–981. doi: 10.1016/j.xphs.2020.11.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xphs.2020.11.013</ArticleId><ArticleId IdType="pubmed">33248058</ArticleId></ArticleIdList></Reference><Reference><Citation>Tchessalov S., Latshaw D., Nulu S., Bentley M., Tharp T., Ewan S., Chen X. Application of first principles primary drying model to lyophilization process design and transfer: Case studies from the industry. J. Pharm. Sci. 2021;110(2021):968–981. doi: 10.1016/j.xphs.2020.11.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xphs.2020.11.013</ArticleId><ArticleId IdType="pubmed">33248058</ArticleId></ArticleIdList></Reference><Reference><Citation>The American Society of Mechanical
Engineers Verification, Validation and Uncertainty
Quantification (VVUQ) 2024. https://www.asme.org/codes-standards/publications-information/verification-validation-uncertainty</Citation></Reference><Reference><Citation>Tian G., Koolivand A., Arden N.S., Lee S., O’Connor T.F. Quality Risk Assessment and mitigation of
pharmaceutical continuous manufacturing using flowsheet modeling
approach. Comput. Chem. Eng. 2019;129:106508. https://www.sciencedirect.com/science/article/abs/pii/S0098135419301139?via%3Dihub July 5.</Citation></Reference><Reference><Citation>Torres-Garcia W., Roy K., Kotanchek T., Edison A., Levine B., Colonna M., Dwarshuis N., Odeh-Couvertier V. Predicting T-cell quality during manufacturing through an artificial intelligence-based integrative multiomics analytical platform. Bioengi. Transl. Med. 2021 doi: 10.1002/btm2.10282. , December 16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/btm2.10282</ArticleId><ArticleId IdType="pmc">PMC9115702</ArticleId><ArticleId IdType="pubmed">35600660</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres-Garcia W., Roy K., Kotanchek T., Edison A., Levine B., Colonna M., Dwarshuis N., Odeh-Couvertier V. Predicting T-cell quality during manufacturing through an artificial intelligence-based integrative multiomics analytical platform. Bioeng. Transl. Med. 2021 doi: 10.1002/btm2.10282. , December 16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/btm2.10282</ArticleId><ArticleId IdType="pmc">PMC9115702</ArticleId><ArticleId IdType="pubmed">35600660</ArticleId></ArticleIdList></Reference><Reference><Citation>Toye D., Sion C., Olmos E., Maillot C., De Isla Natalia. Quality by design to define critical process
parameters for mesenchymal stem cell expansion. Biotechnol. Adv. 2021;50:107765. https://www.sciencedirect.com/science/article/abs/pii/S0734975021000719 May 21.</Citation><ArticleIdList><ArticleId IdType="pubmed">33961977</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food &amp; Drug Administration Pharmaceutical CGMPs for the 21st century - A
Risk-Based Approach Final Report. 2004. https://www.fda.gov/media/77391/download Retrieved August 25, 2023, from.</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration Proposed Regulatory Framework for Modifications to
Artificial Intelligence/Machine Learning (AI/ML)-Based Software
as a Medical Device (SaMD) – Discussion Paper and Request for
Feedback. FDA-2019-0156. 2019. Regulations.govhttps://www.regulations.gov/document/FDA-2019-N-1185-0001 submitted April 2.</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration Artificial Intelligence/Machine Learning (AI/ML)-Based
Software as a Medical Device (SaMD) Action Plan.
FDA-2019-0156. 2021. https://www.fda.gov/media/145022/download January.</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration, Health
Canada Medical Healthcare products Regulatory Agency, Good
Machine Learning Practice for Medical Device Development Guiding
Principles. 2021. Regulations.govhttps://www.regulations.gov/document/FDA-2019-N-1185-0156 FDA-2019-0156. (submitted December 2.</Citation></Reference><Reference><Citation>U.S. Food and Drug, Administration Center for Drug
Evaluation and Research . U.S. Food and Drug Administration; 2021. Development and submission of Near Infrared Analytical
Procedures.https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-submission-near-infrared-analytical-procedures August.</Citation></Reference><Reference><Citation>U.S. Food and Drug, Administration Center for Drug
Evaluation and Research . U.S. Food and Drug Administration; 2021. Development and submission of Near Infrared Analytical
Procedures.https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-submission-near-infrared-analytical-procedures August.</Citation></Reference><Reference><Citation>U.S. Food and Drug, Administration Center for Drug
Evaluation and Research . U.S. Food and Drug Administration; 2021. Development and submission of Near Infrared Analytical
Procedures.https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-submission-near-infrared-analytical-procedures August.</Citation></Reference><Reference><Citation>U.S. Food and Drug, Administration Center for Drug
Evaluation and Research Artificial Intelligence in Drug
Manufacturing. 2023. https://www.fda.gov/media/165743/download?attachment March.</Citation></Reference><Reference><Citation>Van Grouw A., Colonna M.B., Maughon T.S., Shen X., Larey A.M., Moore S.G., Yeago C., Fernández F.M., Edison A.S., Stice S.L., Bowles-Welch A.C. Development of a robust consensus modeling approach for identifying cellular and media metabolites predictive of mesenchymal stromal cell potency. Stem Cells. 2023;41(8):792–808. Aug 1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10427967</ArticleId><ArticleId IdType="pubmed">37279550</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Grouw A., Colonna M.B., Maughon T.S., Shen X., Larey A.M., Moore S.G., Yeago C., Fernández F.M., Edison A.S., Stice S.L., Bowles-Welch A.C. Development of a robust consensus modeling approach for identifying cellular and media metabolites predictive of mesenchymal stromal cell potency. Stem Cells. 2023;41(8):792–808. Aug 1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10427967</ArticleId><ArticleId IdType="pubmed">37279550</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Grouw A., Colonna M.B., Maughon T.S., Shen X., Larey A.M., Moore S.G., Yeago C., Fernández F.M., Edison A.S., Stice S.L., Bowles-Welch A.C. Development of a robust consensus modeling approach for identifying cellular and media metabolites predictive of mesenchymal stromal cell potency. Stem Cells. 2023;41(8):792–808. Aug 1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10427967</ArticleId><ArticleId IdType="pubmed">37279550</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Grouw A., Colonna M.B., Maughon T.S., Shen X., Larey A.M., Moore S.G., Yeago C., Fernández F.M., Edison A.S., Stice S.L., Bowles-Welch A.C. Development of a robust consensus modeling approach for identifying cellular and media metabolites predictive of mesenchymal stromal cell potency. Stem Cells. 2023;41(8):792–808. Aug 1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10427967</ArticleId><ArticleId IdType="pubmed">37279550</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., Escotet-Espinoza M.S., Ierapetritou M. Process analysis and optimization of continuous
pharmaceutical manufacturing using flowsheet
models. Comput. Chem. Eng. 2017;107:77–91. https://www.sciencedirect.com/science/article/abs/pii/S0098135417300947 February 21.</Citation></Reference><Reference><Citation>Xu H., Xiong W., Tsao W.-C., Ramos C., Naghizadeh A., Mohamed M., Metaxas D., Liu D., Li D., Hyun Cho J. PLOS Computational Biology; 2022. In vitro machine learning-based CAR T immunological synapse quality measurements correlate with patient clinical outcomes. March 18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1009883</ArticleId><ArticleId IdType="pmc">PMC8955962</ArticleId><ArticleId IdType="pubmed">35303007</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H., Xiong W., Tsao W.-C., Ramos C., Naghizadeh A., Mohamed M., Metaxas D., Liu D., Li D., Hyun Cho J. PLOS Computational Biology; 2022. In vitro machine learning-based CAR T immunological synapse quality measurements correlate with patient clinical outcomes. March 18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1009883</ArticleId><ArticleId IdType="pmc">PMC8955962</ArticleId><ArticleId IdType="pubmed">35303007</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeago C., Bowles-Welch A., Van Grouw A., Stice S., Shen X., Moore S., Maughon T., Marklein R., Larey A., Fernández F., Edison A., Colonna M. Development of a robust consensus modeling approach
for identifying cellular and media metabolites predictive of
mesenchymal stromal cell potency. Stem Cells. 2023;41(8):792–808. https://academic.oup.com/stmcls/article/41/8/792/7190158 June 3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10427967</ArticleId><ArticleId IdType="pubmed">37279550</ArticleId></ArticleIdList></Reference><Reference><Citation>Yon J.-M., Young Lee S., Won Kim S., Park K., Lee S., Kim H., Jeong I., Jang J., Cho D.-W. Predicting multipotency of human adult stem cells
derived from various donors through deep learning. Sci. Rep. 2022;12:21614. https://www.nature.com/articles/s41598-022-25423-8 December 14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9749643</ArticleId><ArticleId IdType="pubmed">36517519</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu T., Moussa E.M., Witting M., Zhou D., Sinha K., Hirth M., Gastens M., Shang S., Nere N., Somashekar S.C., Alexeenko A., Jameel F. Predictive models of lyophilization process for development, scale-up/tech transfer and manufacturing. Eur. J. Pharm. Biopharm. 2018;128:363–378. doi: 10.1016/j.ejpb.2018.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejpb.2018.05.005</ArticleId><ArticleId IdType="pubmed">29733948</ArticleId></ArticleIdList></Reference><Reference><Citation>Zomer S., Zhang J., Talwar S., Chattoraj S., Hewitt C. Multivariate monitoring for the industrialisation
of a continuous wet granulation tableting
process. Int. J. Pharm. 2018 June 12;547(1-2):506–519. https://www.sciencedirect.com/science/article/abs/pii/S0378517318304320</Citation><ArticleIdList><ArticleId IdType="pubmed">29906561</ArticleId></ArticleIdList></Reference><Reference><Citation>Zomer S., Zhang J., Talwar S., Chattoraj S., Hewitt C. Multivariate monitoring for the industrialisation
of a continuous wet granulation tableting
process. Int. J. Pharm. 2018 June 12;547(1-2):506–519. https://www.sciencedirect.com/science/article/abs/pii/S0378517318304320</Citation><ArticleIdList><ArticleId IdType="pubmed">29906561</ArticleId></ArticleIdList></Reference><Reference><Citation>Zylberberg C., Zhang J., Saha K., Roy K., McFarland R., Lumelsky N., Lin-Gibson S., Haddock R.  National Academy of Medicine; 2017. Manufacturing Cell Therapies:
The Paradigm Shift in Health Care of This Century.https://nam.edu/manufacturing-cell-therapies-the-paradigm-shift-in-health-care-of-this-century/ June 23.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>